1034. Patient Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US Healthcare Settings: Interim Results from the CUSTOMIZE study

BACKGROUND: Cabotegravir and rilpivirine long-acting (CAB+RPV LA) administered by monthly injection demonstrated non-inferiority compared to standard daily oral antiretroviral therapy (ART) at 48 weeks. This novel treatment offers a less frequent dosing alternative to daily oral pills but requires m...

Descripción completa

Detalles Bibliográficos
Autores principales: Garris, Cindy, D’Amico, Ronald, Wannamaker, Paul, Mpofu, Nobuhle, McHorney, Colleen A, Mansukhani, Sonal, Flamm, Jason, Thedinger, Blair, Benson, Paul, Chiriboga-Salazar, Daniela M, Czarnogorski, Maggie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777520/
http://dx.doi.org/10.1093/ofid/ofaa439.1220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777520/
http://dx.doi.org/10.1093/ofid/ofaa439.1220

Ejemplares similares